Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2239373 | 0.83 | HRH3 (0.54) | ALDH1A1KDM4EMEN1KMT2AHRH3 | |
| SCHEMBL2236062 | 0.82 | HRH3 (0.48) | ALDH1A1HTTKDM4EMEN1KMT2A | |
| SCHEMBL2235236 | 0.80 | ALDH1A1 (0.42) | ALDH1A1HTTKDM4EKMT2ACYP2D6 | |
| SCHEMBL2238150 | 0.76 | MCHR1 (0.50) | ALDH1A1KDM4EHRH3 | |
| SCHEMBL1936180 | 0.74 | ALDH1A1 (0.54) | ALDH1A1HTTKDM4EMEN1MAPK1 | |
| SCHEMBL28636678 | 0.74 | ALDH1A1 (0.65) | ALDH1A1HTTKDM4EHRH3SMN1; SMN2 | |
| SCHEMBL2234826 | 0.74 | MAPT (0.49) | ALDH1A1MEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL2518702 | 0.73 | RIPK1 (0.40) | ALDH1A1HTTKDM4EMEN1KMT2A | |
| SCHEMBL12346828 | 0.73 | ALDH1A1 (0.46) | ALDH1A1HTT | |
| SCHEMBL1934369 | 0.71 | ALDH1A1 (0.65) | ALDH1A1HTTKDM4EHRH3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | ALDH1A1 3363/4885HTT 3144/4885KDM4E 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.